File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: Safety and efficacy in an open-label study in 2251 patients

TitleFirst-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: Safety and efficacy in an open-label study in 2251 patients
Authors
KeywordsAngiogenesis
Bevacizumab
First-line
Metastatic breast cancer
Issue Date2011
PublisherOxford University Press. The Journal's web site is located at http://annonc.oxfordjournals.org/
Citation
Annals Of Oncology, 2011, v. 22 n. 3, p. 595-602 How to Cite?
AbstractBackground: First-line bevacizumab combined with chemotherapy significantly improves efficacy versus chemotherapy alone in human epidermal growth factor receptor 2 (HER2)-negative locally recurrent or metastatic breast cancer (LR/mBC). This large, open-label study further assesses first-line bevacizumab with taxane-based chemotherapy in routine oncology practice. Patients and methods: Patients with HER2-negative LR/mBC, Eastern Cooperative Oncology Group (ECOG) performance status (PS) of zero to two and no prior chemotherapy for LR/mBC received bevacizumab 10 mg/kg every 2 weeks or 15 mg/kg every 3 weeks plus taxane-based chemotherapy (or other non-anthracycline chemotherapy) until disease progression, unacceptable toxicity or patient withdrawal. The primary end point was safety; time to progression (TtP) was a secondary end point. Results: Median follow-up in 2251 treated patients was 12.7 months. Median age was 53 years and 94% of patients had ECOG PS of zero or one. Bevacizumab was most commonly administered with single-agent paclitaxel (35%), single-agent docetaxel (33%) or taxane-based combination therapy (10%). The most frequent grade ≥3 adverse event (AE) was neutropenia (5.4%). Grade ≥3 AEs previously associated with bevacizumab included hypertension (4.4%), arterial/venous thromboembolism (3.2%), proteinuria (1.7%) and bleeding (1.4%). No new bevacizumab safety signals were observed. Median TtP was 9.5 months (95% confidence interval 9.1-9.9). Conclusions: The study population in ATHENA was more representative of general oncology practice than populations enrolled into randomised trials, although there may have been some bias towards younger, fitter patients. The safety and efficacy of bevacizumab-taxane therapy in this large study were consistent with results from randomised first-line trials. © The Author 2010. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/134478
ISSN
2015 Impact Factor: 9.269
2015 SCImago Journal Rankings: 4.362
ISI Accession Number ID
Funding AgencyGrant Number
F. Hoffmann-La Roche Ltd, Basel, Switzerland
Roche
Funding Information:

F. Hoffmann-La Roche Ltd, Basel, Switzerland.

References

 

DC FieldValueLanguage
dc.contributor.authorSmith, IEen_HK
dc.contributor.authorPierga, JYen_HK
dc.contributor.authorBiganzoli, Len_HK
dc.contributor.authorCortésFunes, Hen_HK
dc.contributor.authorThomssen, Cen_HK
dc.contributor.authorPivot, Xen_HK
dc.contributor.authorFabi, Aen_HK
dc.contributor.authorXu, Ben_HK
dc.contributor.authorStroyakovskiy, Den_HK
dc.contributor.authorFranke, FAen_HK
dc.contributor.authorKaufman, Ben_HK
dc.contributor.authorMainwaring, Pen_HK
dc.contributor.authorPienkowski, Ten_HK
dc.contributor.authorde Valk, Ben_HK
dc.contributor.authorKwong, Aen_HK
dc.contributor.authorGonzálezTrujillo, JLen_HK
dc.contributor.authorKoza, Ien_HK
dc.contributor.authorPetrakova, Ken_HK
dc.contributor.authorPereira, Den_HK
dc.contributor.authorPritchard, KIen_HK
dc.date.accessioned2011-06-17T09:21:41Z-
dc.date.available2011-06-17T09:21:41Z-
dc.date.issued2011en_HK
dc.identifier.citationAnnals Of Oncology, 2011, v. 22 n. 3, p. 595-602en_HK
dc.identifier.issn0923-7534en_HK
dc.identifier.urihttp://hdl.handle.net/10722/134478-
dc.description.abstractBackground: First-line bevacizumab combined with chemotherapy significantly improves efficacy versus chemotherapy alone in human epidermal growth factor receptor 2 (HER2)-negative locally recurrent or metastatic breast cancer (LR/mBC). This large, open-label study further assesses first-line bevacizumab with taxane-based chemotherapy in routine oncology practice. Patients and methods: Patients with HER2-negative LR/mBC, Eastern Cooperative Oncology Group (ECOG) performance status (PS) of zero to two and no prior chemotherapy for LR/mBC received bevacizumab 10 mg/kg every 2 weeks or 15 mg/kg every 3 weeks plus taxane-based chemotherapy (or other non-anthracycline chemotherapy) until disease progression, unacceptable toxicity or patient withdrawal. The primary end point was safety; time to progression (TtP) was a secondary end point. Results: Median follow-up in 2251 treated patients was 12.7 months. Median age was 53 years and 94% of patients had ECOG PS of zero or one. Bevacizumab was most commonly administered with single-agent paclitaxel (35%), single-agent docetaxel (33%) or taxane-based combination therapy (10%). The most frequent grade ≥3 adverse event (AE) was neutropenia (5.4%). Grade ≥3 AEs previously associated with bevacizumab included hypertension (4.4%), arterial/venous thromboembolism (3.2%), proteinuria (1.7%) and bleeding (1.4%). No new bevacizumab safety signals were observed. Median TtP was 9.5 months (95% confidence interval 9.1-9.9). Conclusions: The study population in ATHENA was more representative of general oncology practice than populations enrolled into randomised trials, although there may have been some bias towards younger, fitter patients. The safety and efficacy of bevacizumab-taxane therapy in this large study were consistent with results from randomised first-line trials. © The Author 2010. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved.en_HK
dc.languageengen_US
dc.publisherOxford University Press. The Journal's web site is located at http://annonc.oxfordjournals.org/en_HK
dc.relation.ispartofAnnals of Oncologyen_HK
dc.subjectAngiogenesisen_HK
dc.subjectBevacizumaben_HK
dc.subjectFirst-lineen_HK
dc.subjectMetastatic breast canceren_HK
dc.subject.meshAged, 80 and over-
dc.subject.meshAntibodies, Monoclonal - administration and dosage-
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols - adverse effects - therapeutic use-
dc.subject.meshBreast Neoplasms - drug therapy - pathology - surgery-
dc.subject.meshNeoplasm Recurrence, Local - drug therapy-
dc.titleFirst-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: Safety and efficacy in an open-label study in 2251 patientsen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0923-7534&volume=22&issue=3&spage=595&epage=602&date=2011&atitle=First-line+bevacizumab+plus+taxane-based+chemotherapy+for+locally+recurrent+or+metastatic+breast+cancer:+safety+and+efficacy+in+an+open-label+study+in+2,251+patients-
dc.identifier.emailKwong, A: avakwong@hkucc.hku.hken_HK
dc.identifier.authorityKwong, A=rp01734en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1093/annonc/mdq430en_HK
dc.identifier.pmid20819780-
dc.identifier.scopuseid_2-s2.0-79952027747en_HK
dc.identifier.hkuros185759en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-79952027747&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume22en_HK
dc.identifier.issue3en_HK
dc.identifier.spage595en_HK
dc.identifier.epage602en_HK
dc.identifier.isiWOS:000287750700014-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridSmith, IE=7404426647en_HK
dc.identifier.scopusauthoridPierga, JY=7007027230en_HK
dc.identifier.scopusauthoridBiganzoli, L=7003746717en_HK
dc.identifier.scopusauthoridCortésFunes, H=7005109664en_HK
dc.identifier.scopusauthoridThomssen, C=7003303447en_HK
dc.identifier.scopusauthoridPivot, X=7003612474en_HK
dc.identifier.scopusauthoridFabi, A=35509014100en_HK
dc.identifier.scopusauthoridXu, B=7404589280en_HK
dc.identifier.scopusauthoridStroyakovskiy, D=41662129900en_HK
dc.identifier.scopusauthoridFranke, FA=22734141300en_HK
dc.identifier.scopusauthoridKaufman, B=7102640009en_HK
dc.identifier.scopusauthoridMainwaring, P=6701860165en_HK
dc.identifier.scopusauthoridPienkowski, T=7004171357en_HK
dc.identifier.scopusauthoridde Valk, B=55271274400en_HK
dc.identifier.scopusauthoridKwong, A=8913654300en_HK
dc.identifier.scopusauthoridGonzálezTrujillo, JL=6506852711en_HK
dc.identifier.scopusauthoridKoza, I=7003793739en_HK
dc.identifier.scopusauthoridPetrakova, K=23091389100en_HK
dc.identifier.scopusauthoridPereira, D=7102217297en_HK
dc.identifier.scopusauthoridPritchard, KI=7102528866en_HK
dc.identifier.citeulike8948992-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats